Evaluate Data

The $6bn raised by drug developers during the third quarter of 2025 marked a significant rise from $4.92bn raised in Q2, with increases in all segments, from small financings to mega-rounds.

Evaluate data show three biopharma initial public offerings on Western stock exchanges in the third quarter, up from two in Q2, all in the US. But China shows similar IPO activity.

Intercept’s Ocaliva withdrawal in the US places the spotlight on emerging PBC candidates like Zydus’s saroglitazar, a PPAR agonist that beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results. Will the withdrawal and policy developments boost Zydus’s prospects?

In Vivo looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.

As blockbuster drugs lose patent protection and sales decline, big pharma companies must replenish aging portfolios with innovative therapies. Some, like Eli Lilly and Novo Nordisk, are rising through new drug launches while others are increasingly reliant on older assets.

As analysts disagree over the future commercial performance of major late-stage therapies, In Vivo looks into the polarized debate surrounding five blockbuster assets.

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

By 2030, the pharmaceutical company leaderboard will be transformed as incretin-based therapies propel Eli Lilly and Novo Nordisk to the top, while companies reliant on aging blockbuster drugs see their dominance wane.

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.